BMI and Treatment Response in Patients With Pulmonary Arterial Hypertension A Meta-analysis

被引:11
作者
McCarthy, Breanne E. [1 ,2 ]
McClelland, Robyn L. [4 ]
Appleby, Dina H. [3 ]
Moutchia, Jude S. [3 ]
Minhas, Jasleen K. [1 ,2 ]
Min, Jeff [1 ,2 ]
Mazurek, Jeremy A. [1 ,2 ]
Smith, K. Akaya [1 ,2 ]
Fritz, Jason S. [1 ,2 ]
Pugliese, Steven C. [1 ,2 ]
Urbanowicz, Ryan J. [4 ]
Holmes, John H. [4 ]
Palevsky, Harold I. [1 ,2 ]
Kawut, Steven M. [1 ,2 ,4 ]
Al-Naamani, Nadine [1 ,2 ]
机构
[1] Univ Penn, Dept Med, Philadelphia, PA 19104 USA
[2] Univ Penn, Departmentof Biostat Epidemiol & Informat, Philadelphia, PA 19104 USA
[3] Univ Penn, Perelman Sch Med, Philadelphia, PA USA
[4] Univ Washington Sch Publ Hlth, Dept Biostat, Seattle, WA USA
基金
美国国家卫生研究院;
关键词
BMI; meta-analysis; obesity; pulmonary arterial hypertension; RECEPTOR ANTAGONIST; ORAL TREPROSTINIL; DOUBLE-BLIND; THERAPY; SURVIVAL; EFFICACY; REGISTRY; OBESITY; EPIDEMIOLOGY; AMBRISENTAN;
D O I
10.1016/j.chest.2022.02.041
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
BACKGROUND: Obesity is increasingly prevalent in pulmonary arterial hypertension (PAH) but is associated with improved survival, creating an "obesity paradox " in PAH. It is unknown if the improved outcomes could be attributable to obese patients deriving a greater benefit from PAH therapies. RESEARCH QUESTION: Does BMI modify treatment effectiveness in PAH? STUDY DESIGN AND METHODS: Using individual participant data, a meta-analysis was conducted of phase III, randomized, placebo-controlled trials of treatments for PAH submitted for approval to the U.S. Food and Drug Administration from 2000 to 2015. Primary outcomes were change in 6-min walk distance (6MWD) and World Health Organization (WHO) functional class. RESULTS: A total of 5,440 participants from 17 trials were included. Patients with overweight and obesity had lower baseline 6MWD and were more likely to be WHO functional class III or IV. Treatment was associated with a 27.01-m increase in 6MWD (95% CI, 21.58-32.45; P < .001) and lower odds of worse WHO functional class (OR, 0.58; 95% CI, 0.48-0.70; P < .001). For every 1 kg/m(2) increase in BMI, 6MWD was reduced by 0.66 m (P = .07); there was no significant effect modification of treatment response in 6MWD according to BMI (P for interaction = .34). Higher BMI was not associated with odds of WHO functional class at end of follow-up; however, higher BMI attenuated the treatment response such that every 1 kg/m(2) increase in BMI increased odds of worse WHO functional class by 3% (OR, 1.03; P for interaction = .06). INTERPRETATION: Patients with overweight and obesity had lower baseline 6MWD and worse WHO functional class than patients with normal weight with PAH. Higher BMI did not modify the treatment response for change in 6MWD, but it attenuated the treatment response for WHO functional class. PAH trials should include participants representative of all weight groups to allow for assessment of treatment heterogeneity and mechanisms.
引用
收藏
页码:436 / 447
页数:12
相关论文
共 55 条
[41]   Individual participant data meta-analysis to examine interactions between treatment effect and participant-level covariates: Statistical recommendations for conduct and planning [J].
Riley, Richard D. ;
Debray, Thomas P. A. ;
Fisher, David ;
Hattle, Miriam ;
Marlin, Nadine ;
Hoogland, Jeroen ;
Gueyffier, Francois ;
Staessen, Jan A. ;
Wang, Jiguang ;
Moons, Karel G. M. ;
Reitsma, Johannes B. ;
Ensor, Joie .
STATISTICS IN MEDICINE, 2020, 39 (15) :2115-2137
[42]   Bosentan therapy for pulmonary arterial hypertension [J].
Rubin, LJ ;
Badesch, DB ;
Barst, RJ ;
Galiè, N ;
Black, CM ;
Keogh, A ;
Pulido, T ;
Frost, A ;
Roux, S ;
Leconte, I ;
Landzberg, M ;
Simonneau, G .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (12) :896-903
[43]   Safety and efficacy of sitaxsentan 50 and 100 mg in patients with pulmonary arterial hypertension [J].
Sandoval, Julio ;
Torbicki, Adam ;
Souza, Rogerio ;
Ramirez, Alicia ;
Kurzyna, Marcin ;
Jardim, Carlos ;
Jerjes-Sanchez Diaz, Carlos ;
Teal, Simon A. ;
Hwang, Lie-Ju ;
Pulido, Tomas .
PULMONARY PHARMACOLOGY & THERAPEUTICS, 2012, 25 (01) :33-39
[44]   Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension - A double-blind, randomized, placebo-controlled trial [J].
Simonneau, G ;
Barst, RJ ;
Galie, N ;
Naeije, R ;
Rich, S ;
Bourge, RC ;
Keogh, A ;
Oudiz, R ;
Frost, A ;
Blackburn, SD ;
Crow, JW ;
Rubin, LJ .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2002, 165 (06) :800-804
[45]   Selexipag for the Treatment of Pulmonary Arterial Hypertension [J].
Sitbon, Olivier ;
Channick, Richard ;
Chin, Kelly M. ;
Frey, Aline ;
Gaine, Sean ;
Galie, Nazzareno ;
Ghofrani, Hossein-Ardeschir ;
Hoeper, Marius M. ;
Lang, Irene M. ;
Preiss, Ralph ;
Rubin, Lewis J. ;
Di Scala, Lilla ;
Tapson, Victor ;
Adzerikho, Igor ;
Liu, Jinming ;
Moiseeva, Olga ;
Zeng, Xiaofeng ;
Simonneau, Gerald ;
McLaughlin, Vallerie V. .
NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (26) :2522-2533
[46]   Statistical Analysis of Individual Participant Data Meta-Analyses: A Comparison of Methods and Recommendations for Practice [J].
Stewart, Gavin B. ;
Altman, Douglas G. ;
Askie, Lisa M. ;
Duley, Lelia ;
Simmonds, Mark C. ;
Stewart, Lesley A. .
PLOS ONE, 2012, 7 (10)
[47]   Oral Treprostinil for the Treatment of Pulmonary Arterial Hypertension in Patients Receiving Background Endothelin Receptor Antagonist and Phosphodiesterase Type 5 Inhibitor Therapy (The FREEDOM-C2 Study) A Randomized Controlled Trial [J].
Tapson, Victor F. ;
Jing, Zhi-Cheng ;
Xu, Kai-Feng ;
Pan, Lei ;
Feldman, Jeremy ;
Kiely, David G. ;
Kotlyar, Eugene ;
McSwain, C. Shane ;
Laliberte, Kevin ;
Arneson, Carl ;
Rubin, Lewis J. .
CHEST, 2013, 144 (03) :952-958
[48]  
Taraseviciute A, 2006, EUR J MED RES, V11, P198
[49]   Pulmonary arterial hypertension: pathogenesis and clinical management [J].
Thenappan, Thenappan ;
Ormiston, Mark L. ;
Ryan, John J. ;
Archer, Stephen L. .
BMJ-BRITISH MEDICAL JOURNAL, 2018, 360
[50]   Evolving Epidemiology of Pulmonary Arterial Hypertension [J].
Thenappan, Thenappan ;
Ryan, John J. ;
Archer, Stephen L. .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2012, 186 (08) :707-709